Jason Rhodes is a general partner at Atlas Venture, and is a founder, the executive chairman, and acting CEO of Disarm Therapeutics, the chairman and previously founding CEO of Torus Therapeutics, and is on the boards of Replimune, Accent Therapeutics and Bicycle Therapeutics.
Prior to joining Atlas Venture in 2014, Jason was president of Epizyme, where he charted the company’s strategic course from a private, research-stage business into the clinic and through a successful IPO in 2013. He established and was responsible for all business and finance functions and led the company’s partnerships with Celgene, GSK, and others. Prior to Epizyme, Jason led business development at Alnylam, where he was a member of the leadership team and responsible for corporate partnerships with companies including Roche, Takeda, GSK, Isis, Cubist, Kyowa Hakko Kirin, and Medtronic as well as the spin out of Regulus Therapeutics. Before Alnylam, Jason was a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including Ironwood Pharmaceuticals, FoldRx (purchased by Pfizer), Mersana Therapeutics and Tetraphase. Earlier in his career, Jason worked on new business entrance, product strategy, and commercialization projects with biopharma and high tech companies.
Jason received his BA from Yale University and his MBA from the Wharton School at the University of Pennsylvania. He is a member of the advisory board of the Harvard Institute for RNA Medicine, the BIDMC Board of Overseers, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council.